James P. Crowley: How Combining Vitamin D analogs with Chemotherapy Impacts Survival Outcomes
James P. Crowley, Professor of Medicine Emeritus at Brown University, Captain at U.S. Navy Reserve, shared a post on LinkedIn:
“The findings from this trial set the stage for larger clinical studies designed to evaluate how combining vitamin D analogs with chemotherapy or other cancer therapies impacts survival outcomes.
In addition, future work is needed to test whether baseline vitamin D receptor expression can serve as a reliable biomarker of patient responses to combination therapies, including vitamin D analogs.
‘This study is an important step forward for the use of a vitamin D analog as a stromal remodeling therapy that can overcome therapeutic resistance in pancreatic,’ says Perez.
‘It was built upon foundational basic research at the Salk Institute, validates those preclinical findings in patients, and provides a road map for future studies that could someday establish a new treatment standard.'”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH